Clinic
Winslow Memorial Hospital INC
Winslow Memorial Hospital INC was paid $38.01M by Medicaid between Jan 2018 and Dec 2024, across 183 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoWINSLOW MEMORIAL HOSPITAL INC
WINSLOW, AZ 86047
WINSLOW, AZ 86047
33aNPI1477653889assigned 09/25/2006
33bProvider typeRural Health Clinic/Center
28Total paid$38.01M
24GClaims420,831
24DCodes billed183
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in Arizona
Rank by total paid#1 of 34
Median peer was paid$666K
This provider vs. median57×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,789 | $3.76M | |
| 2019 | 55,712 | $4.85M | |
| 2020 | 52,737 | $4.81M | |
| 2021 | 67,196 | $6.04M | |
| 2022 | 75,636 | $7.39M | |
| 2023 | 67,945 | $6.35M | |
| 2024incomplete | 49,816 | $4.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 17,631 | 15,015 | $6.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 16,594 | 15,220 | $5.85M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 9,901 | 8,667 | $5.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 2,926 | 2,718 | $4.59M |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 11% | 15,271 | 12,018 | $4.09M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.9% | 10,731 | 7,712 | $2.24M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.5% | 4,731 | 4,320 | $2.08M |
| 72125 | Computed tomography, cervical spine; without contrast material | 5.3% | 2,106 | 1,973 | $2.01M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.9% | 714 | 688 | $1.09M |
| G0378 | Hospital observation service, per hour | 2.0% | 5,750 | 2,090 | $746K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.7% | 772 | 725 | $660K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 3,115 | 2,972 | $467K |
171 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 323 | $436K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 2,083 | $322K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,627 | $236K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,729 | $209K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 139 | $117K |
| 70486 | <1% | 465 | $116K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 6,652 | $100K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,364 | $81K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,236 | $78K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,658 | $45K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 330 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 667 | $38K |
| 80053 | Comprehensive metabolic panel | <1% | 22,401 | $33K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 291 | $29K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 39 | $23K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,381 | $21K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 604 | $17K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 696 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,720 | $13K |
| 71045 | Radiologic examination, chest; single view | <1% | 7,484 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,996 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,283 | $13K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 682 | $13K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,539 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,517 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,074 | $11K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $11K |
| 84439 | <1% | 860 | $11K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 27 | $10K |
| 80061 | Lipid panel | <1% | 1,612 | $8K |
| 86850 | <1% | 757 | $8K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 278 | $8K |
| 82607 | <1% | 170 | $6K | |
| 71250 | <1% | 14 | $6K | |
| 73030 | <1% | 220 | $6K | |
| 94002 | <1% | 15 | $6K | |
| 96367 | <1% | 1,081 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,911 | $5K |
| 73564 | <1% | 73 | $5K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 634 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 145 | $5K |
| 87088 | <1% | 4,092 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,594 | $5K |
| 83880 | <1% | 2,410 | $4K | |
| 12001 | <1% | 25 | $4K | |
| 83690 | <1% | 6,881 | $4K | |
| 73130 | <1% | 187 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,194 | $4K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,789 | $4K |
| 73630 | <1% | 150 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,497 | $3K |
| 81000 | <1% | 9,592 | $3K | |
| 86900 | <1% | 1,047 | $2K | |
| A9270 | Non-covered item or service | <1% | 2,932 | $2K |
| 73610 | <1% | 94 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,049 | $2K |
| 84484 | <1% | 6,406 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,303 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 717 | $2K |
| 73562 | <1% | 57 | $1K | |
| 85610 | <1% | 5,915 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,615 | $1K |
| 85007 | <1% | 3,606 | $921.22 | |
| 83605 | <1% | 4,213 | $854.15 | |
| 81025 | <1% | 2,246 | $843.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 827 | $823.55 |
| 84703 | <1% | 2,620 | $803.96 | |
| 94760 | <1% | 413 | $801.92 | |
| 83735 | <1% | 7,077 | $749.81 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 799 | $737.73 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 157 | $733.72 |
| 73110 | <1% | 29 | $694.66 | |
| 72100 | <1% | 14 | $690.63 | |
| 85027 | <1% | 3,950 | $611.12 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 130 | $581.60 |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 25 | $563.47 |
| 85730 | <1% | 4,340 | $549.51 | |
| 90715 | <1% | 990 | $484.18 | |
| 85379 | <1% | 1,301 | $436.65 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,121 | $405.18 |
| 87081 | <1% | 256 | $399.94 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,126 | $395.56 |
| 80320 | <1% | 6,951 | $370.67 | |
| 80329 | <1% | 4,019 | $366.96 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 236 | $350.75 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,133 | $335.74 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,288 | $308.43 |
| 82140 | <1% | 505 | $293.66 | |
| 87040 | <1% | 1,631 | $259.62 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 75 | $234.45 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,566 | $232.54 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,456 | $226.07 |
| 82150 | <1% | 205 | $223.76 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,573 | $218.57 |
| 82550 | <1% | 679 | $202.69 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 338 | $176.37 |
| 86780 | <1% | 47 | $167.72 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,900 | $153.80 |
| 96376 | <1% | 3,764 | $146.34 | |
| 84702 | <1% | 102 | $139.64 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,445 | $130.92 |
| 82805 | <1% | 640 | $108.61 | |
| 86140 | <1% | 12 | $86.09 | |
| 87070 | <1% | 28 | $83.44 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 310 | $82.40 |
| 86901 | <1% | 1,090 | $77.15 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,604 | $56.31 |
| 88304 | <1% | 122 | $50.54 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,292 | $45.97 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 375 | $43.07 |
| 82553 | <1% | 212 | $41.29 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,751 | $38.24 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,140 | $38.06 |
| 87486 | <1% | 603 | $36.65 | |
| 87581 | <1% | 604 | $36.65 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 759 | $32.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 911 | $32.05 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 741 | $21.26 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 216 | $18.71 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 881 | $16.91 |
| A4217 | Sterile water/saline, 500 ml | <1% | 19 | $16.16 |
| 83615 | <1% | 228 | $14.55 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,002 | $13.43 |
| 87077 | <1% | 139 | $11.32 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 57 | $11.17 |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 60 | $9.46 |
| 82948 | <1% | 461 | $6.26 | |
| 81002 | <1% | 154 | $5.09 | |
| 85651 | <1% | 197 | $4.42 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,043 | $4.00 |
| 86592 | <1% | 44 | $3.18 | |
| 81001 | <1% | 124 | $2.83 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 85 | $0.12 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 1,181 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 82 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,603 | $0.00 |
| 3044F | 0% | 252 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 161 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 281 | $0.00 |
| 94762 | 0% | 72 | $0.00 | |
| 0011A | 0% | 49 | $0.00 | |
| 96368 | 0% | 73 | $0.00 | |
| 82746 | 0% | 12 | $0.00 | |
| 0012A | 0% | 81 | $0.00 | |
| 94644 | 0% | 58 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 26 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 92 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 28 | $0.00 |
| 0064A | 0% | 14 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 28 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
| 85018 | 0% | 13 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 13 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 367 | $0.00 |
| 82009 | 0% | 46 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 107 | $0.00 |
| 87186 | 0% | 101 | $0.00 | |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 42 | $0.00 |
| 74018 | 0% | 26 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 17 | $0.00 |
| 87641 | 0% | 28 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 58 | $0.00 |
| 84145 | 0% | 29 | $0.00 | |
| 86703 | 0% | 26 | $0.00 | |
| 83540 | 0% | 15 | $0.00 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| 86922 | 0% | 16 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 19 | $0.00 |
| 99442 | 0% | 83 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 46 | $0.00 |
| 94664 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialUDALL, TRAVIS (CEO)
| Provider | Location | Paid |
|---|---|---|
| Winslow Memorial Hospital INC | Winslow, AZ | $8K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.